KR20240012436A - 복수의 타스퀴니모드 입자 및 그 용도 - Google Patents
복수의 타스퀴니모드 입자 및 그 용도 Download PDFInfo
- Publication number
- KR20240012436A KR20240012436A KR1020237042849A KR20237042849A KR20240012436A KR 20240012436 A KR20240012436 A KR 20240012436A KR 1020237042849 A KR1020237042849 A KR 1020237042849A KR 20237042849 A KR20237042849 A KR 20237042849A KR 20240012436 A KR20240012436 A KR 20240012436A
- Authority
- KR
- South Korea
- Prior art keywords
- particles
- cancer
- range
- tasquinimod
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Powder Metallurgy (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21175623 | 2021-05-25 | ||
| EP21175623.4 | 2021-05-25 | ||
| PCT/EP2022/063887 WO2022248401A1 (en) | 2021-05-25 | 2022-05-23 | A plurality of tasquinimod particles and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240012436A true KR20240012436A (ko) | 2024-01-29 |
Family
ID=76098832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237042849A Pending KR20240012436A (ko) | 2021-05-25 | 2022-05-23 | 복수의 타스퀴니모드 입자 및 그 용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12485095B2 (https=) |
| EP (1) | EP4346773B1 (https=) |
| JP (1) | JP2024520307A (https=) |
| KR (1) | KR20240012436A (https=) |
| CN (1) | CN117295492A (https=) |
| AU (1) | AU2022281056A1 (https=) |
| BR (1) | BR112023023715A2 (https=) |
| CA (1) | CA3218977A1 (https=) |
| ES (1) | ES3048983T3 (https=) |
| IL (1) | IL308542A (https=) |
| MX (1) | MX2023013301A (https=) |
| PL (1) | PL4346773T3 (https=) |
| WO (1) | WO2022248401A1 (https=) |
| ZA (1) | ZA202311594B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025228998A1 (en) * | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SG186430A1 (en) | 2010-07-09 | 2013-01-30 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| US10213422B2 (en) | 2014-04-14 | 2019-02-26 | Yale University | Compositions and methods of inhibiting histone deacetylases |
| JP6647287B2 (ja) | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
| MX379401B (es) | 2014-11-19 | 2025-03-11 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| WO2018105943A1 (ko) | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
| BR112023000892A2 (pt) | 2020-07-23 | 2023-02-07 | Univ Erasmus Med Ct Rotterdam | Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor |
| ES3057099T3 (en) | 2021-01-18 | 2026-02-26 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
-
2022
- 2022-05-23 PL PL22730773.3T patent/PL4346773T3/pl unknown
- 2022-05-23 CN CN202280034543.8A patent/CN117295492A/zh active Pending
- 2022-05-23 WO PCT/EP2022/063887 patent/WO2022248401A1/en not_active Ceased
- 2022-05-23 JP JP2023570225A patent/JP2024520307A/ja active Pending
- 2022-05-23 IL IL308542A patent/IL308542A/en unknown
- 2022-05-23 US US18/289,738 patent/US12485095B2/en active Active
- 2022-05-23 ES ES22730773T patent/ES3048983T3/es active Active
- 2022-05-23 EP EP22730773.3A patent/EP4346773B1/en active Active
- 2022-05-23 BR BR112023023715A patent/BR112023023715A2/pt unknown
- 2022-05-23 KR KR1020237042849A patent/KR20240012436A/ko active Pending
- 2022-05-23 CA CA3218977A patent/CA3218977A1/en active Pending
- 2022-05-23 AU AU2022281056A patent/AU2022281056A1/en active Pending
- 2022-05-23 MX MX2023013301A patent/MX2023013301A/es unknown
-
2023
- 2023-12-18 ZA ZA2023/11594A patent/ZA202311594B/en unknown
-
2025
- 2025-11-24 US US19/399,224 patent/US20260076908A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202311594B (en) | 2025-04-30 |
| AU2022281056A1 (en) | 2023-11-30 |
| IL308542A (en) | 2024-01-01 |
| JP2024520307A (ja) | 2024-05-24 |
| BR112023023715A2 (pt) | 2024-02-20 |
| EP4346773C0 (en) | 2025-07-02 |
| US20240285532A1 (en) | 2024-08-29 |
| CA3218977A1 (en) | 2022-12-01 |
| EP4346773B1 (en) | 2025-07-02 |
| EP4346773A1 (en) | 2024-04-10 |
| CN117295492A (zh) | 2023-12-26 |
| WO2022248401A1 (en) | 2022-12-01 |
| ES3048983T3 (en) | 2025-12-12 |
| US12485095B2 (en) | 2025-12-02 |
| US20260076908A1 (en) | 2026-03-19 |
| PL4346773T3 (pl) | 2025-11-03 |
| MX2023013301A (es) | 2023-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20010040484A (ko) | 셀레코시브 조성물 | |
| JPH0122245B2 (https=) | ||
| EA029096B1 (ru) | Твердая лекарственная форма для перорального введения, содержащая метилналтрексон | |
| KR20120137374A (ko) | 수의학적 조성물 | |
| CN101069675A (zh) | 用于减轻痉挛状态的体征和症状的方法 | |
| MX2012000048A (es) | Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos. | |
| JP5775302B2 (ja) | 味のマスキングが改善された押出物 | |
| US20260076908A1 (en) | Plurality of tasquinimod particles and use thereof | |
| JP2020007355A (ja) | 異常な細胞成長を処置するための組成物および方法 | |
| JP2021512860A (ja) | 薬学的製剤 | |
| KR20180087114A (ko) | 모사프리드 또는 이의 염을 포함하는 약제학적 제제 및 이의 제조방법 | |
| CN110582278B (zh) | 药物组合物及其用途 | |
| HK40107035A (en) | A plurality of tasquinimod particles and use thereof | |
| HK40107035B (en) | A plurality of tasquinimod particles and use thereof | |
| CN112156096B (zh) | 叶酸缓释组合物、缓释制剂及其应用 | |
| TW202313072A (zh) | 檸檬酸鐵之兒科調配物 | |
| WO2022072099A9 (en) | Immediate release dosage forms, methods of making and using | |
| JPS6136217A (ja) | 経口投与用持効性製剤 | |
| DE102011053068A1 (de) | Darreichungsform mit stabilisierten Wirkstoffpartikeln | |
| WO2026032974A1 (en) | Formulation of linaprazan glurate | |
| TW202602438A (zh) | 藥物成分、劑型及其製備及使用方法 | |
| KR20170112509A (ko) | 멜라토닌 함유 경구용 고형제제 및 그 제조방법 | |
| CN121774901A (zh) | 托吡司特药物组合物、制备方法及应用 | |
| CN114903866A (zh) | Raf激酶抑制剂胶囊组合物的制备方法 | |
| EA040951B1 (ru) | Лекарственные формы цис-4-[2-{[(3s,4r)-3-фтороксан-4-ил]амино}-8-(2,4,6-трихлоранилино)-9н-пурин-9-ил]-1-метилциклогексан-1-карбоксамида и их применение в способе лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231211 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250513 Comment text: Request for Examination of Application |